c-myc inhibitor 7

C-Myc Inhibitor 7, serving as both a c-Myc inhibitor and a multi-target protein degrader, effectively degrades proteins c-MYC, CK1α, GSPT1, and IKZF1 2 3 across various tumor cell types. It holds potential for research into diseases associated with high c-Myc expression, including cancer, cardiovascular and cerebrovascular conditions, and viral infections.

Idarubicin hydrochloride (Zavedos), a hydrochloride salt form of Idarubicin, is a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells ( IC50: 3.3 ng mL).

Antiproliferative agent-64 (Compound 76) functions as an inhibitor of the eukaryotic translation initiation factor 4E (eIF4E) and disrupts the secondary structure of mRNA, thereby hindering protein translation. It inhibits the 5' untranslated region (5'UTR) of c-Myc with an EC50 of 1.2 nM and the 5'UTR of tubulin with an EC50 of 40 nM. Additionally, Antiproliferative agent-64 suppresses the proliferation of MDA-MB-231 cells with an EC50 of 7 nM.

c-Mycligand 1 is a c-Myc inhibitor and functions as a ligand for target proteins in PROTAC (Proteolysis Targeting Chimeras). It is utilized in the synthesis of PROTAC c-Myc inhibitor 7.

γ-Sitosterol acts as an inhibitor of c-Myc. It suppresses the proliferation of cancer cells MCF-7 and A549, with IC50 values of 240.73 μg mL and 696.6 μg mL, respectively. γ-Sitosterol induces cell cycle arrest at the G2 M phase and triggers apoptosis (apoptosis). Additionally, it upregulates the expression of cyclin B E [cyclin B E].